MedTrace Logo

Carbon-11 Acetate and Fludeoxyglucose F 18 PET Scan of the Bone in Patients With Metastatic Prostate Cancer That Has Spread to the Bone

NCT00392938 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 11

Last updated 2017-03-13

No results posted yet for this study

Summary

RATIONALE: Imaging procedures, such as PET scan, may help doctors predict a patient's response to treatment and help plan the best treatment.

PURPOSE: This clinical trial is studying carbon-11 acetate and fludeoxyglucose F 18 PET scan of the bone in patients with metastatic prostate cancer that has spread to the bone.

Conditions

Interventions

DRUG

antiandrogen therapy

DRUG

docetaxel

DIAGNOSTIC_TEST

C-11 acetate PET scan

DIAGNOSTIC_TEST

F-18 FDG PET scan

DIAGNOSTIC_TEST

Tc-99m bone scan

DIAGNOSTIC_TEST

CT scan of the chest, abdomen and pelvis

Sponsors & Collaborators

Principal Investigators

  • Evan Y. Yu, MD · Seattle Cancer Care Alliance

Eligibility

Min Age
18 Years
Max Age
120 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-12-31
Primary Completion
2010-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00392938 on ClinicalTrials.gov